{"id":212098,"date":"2017-03-01T05:46:05","date_gmt":"2017-03-01T10:46:05","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/rare-but-fatal-pediatric-brain-tumor-may-be-stopped-with-new-molecule-medical-news-today.php"},"modified":"2017-03-01T05:46:05","modified_gmt":"2017-03-01T10:46:05","slug":"rare-but-fatal-pediatric-brain-tumor-may-be-stopped-with-new-molecule-medical-news-today","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/rare-but-fatal-pediatric-brain-tumor-may-be-stopped-with-new-molecule-medical-news-today.php","title":{"rendered":"Rare but fatal pediatric brain tumor may be stopped with new molecule &#8211; Medical News Today"},"content":{"rendered":"<p><p>Researchers may have found a molecule that inhibits the growth of  a rare but fatal tumor that occurs in children, called diffuse  intrinsic pontine glioma.  <\/p>\n<p>    Diffuse intrinsic pontine glioma (DIPG) is    a pediatric brain tumor that mainly affects children under 10    years of age.  <\/p>\n<p>    Approximately 300 children - usually between 5 and 9 years old    - are diagnosed with DIPG every year. DIPGs are located in the    brain's pons - a brain region that controls many of the body's    vital functions, including breathing and heart rate.  <\/p>\n<p>    DIPGs are extremely aggressive and difficult to treat, so being    diagnosed with the tumor typically results in death within a    year.  <\/p>\n<p>    New research, however, offers hope for treating DIPG.    Scientists from Northwestern University in Evanston, IL, may    have found a molecule that could stop the development of the    tumor. The team was led by Ali Shilatifard, Robert Francis    Furchgott professor of biochemistry and pediatrics, and chair    of biochemistry and molecular genetics at Northwestern    University's Feinberg School of Medicine.  <\/p>\n<p>    The new findings - published in the journal Nature Medicine    - build on research that Shilatifard and colleagues have    carried out in the past. Shilatifard and his team identified    the pathway through which a genetic mutation causes cancer in a study published in the magazine Science, and a    follow-up study - conducted in collaboration with    Rintaro Hashizume and his team - used this knowledge to test    the effects of pharmacological therapy on DIPG in mice.  <\/p>\n<p>    The latter study inhibited the previously identified genetic    pathway and successfully prolonged the life of mice by 20 days.    The drug was administered through the mice's abdomen, but in    this latest research, the team set out to investigate whether    injecting the cells into the mice's brainstem would have more    robust effects.  <\/p>\n<p>    The scientists sampled tumor cell lines from an untreated    patient and injected them into a mouse's brainstem, where it    grew into a tumor. Subsequently, the scientists treated the    mouse with a BET bromodomain inhibitor and went on to    clinically monitor the tumor.  <\/p>\n<p>    The BET bromodomain inhibitor has proven efficacious in several cancer models    before.  <\/p>\n<p>    In this study, by using the inhibitor, bromodomain    proteins could no longer bind to the histone H3K27M - a mutant    protein found in 80 percent of DIPG tumors. BET inhibitors    stopped the proliferation of tumor cells, and forced them to    differentiate into other cells instead. This successfully    stopped tumor growth.  <\/p>\n<p>    The study's first author, Andrea Piunti - a postdoctoral fellow    in Shilatifard's laboratory in biochemistry and molecular    genetics at Northwestern University Feinberg School of Medicine    - suggests that BET inhibitors should next be tested in a    pediatric trial to treat DIPG, especially since the drugs are    already being tested for pediatric leukemia.  <\/p>\n<p>      \"To the best of our knowledge, this is the most effective      molecule so far in treating this tumor. Every other therapy      that has been tried so far has failed.\"    <\/p>\n<p>      Ali Shilatifard, senior author    <\/p>\n<p>    The senior author also notes that the currently available    radiation therapy is ineffective in treating    DIPG; it only adds a few months to the patients' survival.  <\/p>\n<p>    Shilatifard comments on the importance of Northwestern    University for making this research possible:  <\/p>\n<p>    \"This work could not have been done anywhere in the world    except Northwestern Medicine, because of all the scientists and    physicians who have been recruited here during the past five    years and how they work together to link basic scientific    research to the clinic,\" Shilatifard says. \"This discovery is    the perfect example of how we take basic science discoveries    and translate them to cure diseases at Northwestern Medicine.\"  <\/p>\n<p>    Learn how childhood cancer    treatment may hinder later-life sexual relationships.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>View original post here:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.medicalnewstoday.com\/articles\/316110.php\" title=\"Rare but fatal pediatric brain tumor may be stopped with new molecule - Medical News Today\">Rare but fatal pediatric brain tumor may be stopped with new molecule - Medical News Today<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Researchers may have found a molecule that inhibits the growth of a rare but fatal tumor that occurs in children, called diffuse intrinsic pontine glioma. Diffuse intrinsic pontine glioma (DIPG) is a pediatric brain tumor that mainly affects children under 10 years of age.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/rare-but-fatal-pediatric-brain-tumor-may-be-stopped-with-new-molecule-medical-news-today.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-212098","post","type-post","status-publish","format-standard","hentry","category-genetic-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/212098"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=212098"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/212098\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=212098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=212098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=212098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}